Gene Therapy: Treating Diseases by Fixing Faulty Genes

Gene therapy means treating a disease by adding a working gene, fixing a faulty gene, or silencing a harmful gene inside a patient's cells. Instead of only managing symptoms, it aims at the genetic root cause.

This matters because many disorders, such as severe combined immunodeficiency (SCID) and some inherited blindness, come from a single faulty gene. Giving cells a correct copy can restore a missing protein and change the course of the disease.

Key Concepts

Vector in gene therapy is often a modified virus that delivers DNA but cannot cause disease. Ex vivo therapy removes cells, corrects them outside the body, and returns them. In vivo therapy delivers the gene directly inside the body. ADA-SCID is an immune disorder caused by missing adenosine deaminase enzyme. Expression means the delivered gene is switched on and makes its protein.

How It Works

1. Doctors identify the faulty gene causing the disease.
2. A correct copy of the gene is prepared and packed into a safe vector.
3. Target cells are collected (ex vivo) or the vector is given to the body (in vivo).
4. The vector delivers the gene into the target cells.
5. Cells start making the missing protein.
6. Patients are monitored for benefit, immune reactions and long-term safety.

Worked Example

In an ex vivo trial plan, doctors collect 200 million blood stem cells from a patient. Laboratory tests show 40 percent receive the working gene. Step 1: corrected cells = 200,000,000 x 0.40 = 80,000,000 cells. Step 2: if 75 percent of corrected cells survive processing and return, usable corrected cells = 80,000,000 x 0.75 = 60,000,000 cells. Step 3: these 60 million cells are returned to the patient, where each can divide and produce many corrected blood cells over time. The arithmetic shows why delivery and survival rates strongly affect treatment strength.

Common Misconceptions

• Gene therapy changes every cell in the body. It targets specific cells; most other cells remain unchanged.
• It always edits the DNA permanently. Some methods add a gene copy without cutting DNA, and effects depend on cell life span.
• Approved treatments exist for all genetic diseases. Only some diseases have approved therapies; many are still in clinical trials.

Real-World Applications

Approved examples include Luxturna for an inherited retinal disease (2017) and Zolgensma for spinal muscular atrophy (2019), plus ex vivo therapies for ADA-SCID in some regions. Research continues for haemophilia, sickle cell disease and thalassemia, including gene editing approaches.

In summary, gene therapy delivers a working gene to the right cells so they can make a needed protein. It is powerful but carefully tested, and it offers hope where medicines alone cannot fix the cause.